Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
about
Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathyIntermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J MiceThe Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and AgingSyntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EBLong-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice.Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers.The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy.Using Human iPSC-Derived Neurons to Model TAU Aggregation.miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo.Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits.Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB PerspectiveAutophagy as an essential cellular antioxidant pathway in neurodegenerative disease.Prion degradation pathways: Potential for therapeutic intervention.Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine.Mitochondria as a target for neuroprotection: implications for Alzheimer´s disease.Rab7A regulates tau secretion.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Therapeutic Strategies for Restoring Tau Homeostasis.A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.Autophagy in the presynaptic compartment in health and disease.Comparative analysis of autophagy and tauopathy related markers in cerebral ischemia and Alzheimer's disease animal models.Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability.Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.Hepatic S6K1 Partially Regulates Lifespan of Mice with Mitochondrial Complex I Deficiency.A seeding based cellular assay of tauopathy.Therapeutic implication of autophagy in neurodegenerative diseases.Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer's Disease.Probing the correlation of neuronal loss, neurofibrillary tangles, and cell death markers across the Alzheimer's disease Braak stages: a quantitative study in humans.Neuroinflammatory Gene Regulation, Mitochondrial Function, Oxidative Stress, and Brain Lipid Modifications With Disease Progression in Tau P301S Transgenic Mice as a Model of Frontotemporal Lobar Degeneration-Tau.Galectin-8-mediated selective autophagy protects against seeded tau aggregation.Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model.Tau-based therapies in neurodegeneration: opportunities and challenges.Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.Association Between Autophagy and Neurodegenerative Diseases.Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits.
P2860
Q27301246-BF7502A0-9B34-41AB-8F00-620660D856F3Q28275005-A757B413-998A-45A8-B65D-C8F1C22211E3Q28276378-E9FD000E-6AC3-414C-9471-1F7DCA71518FQ33949740-05935972-27CB-4177-83D8-F1EB4F365AD7Q34342483-9E7C1C2C-7811-42E1-BC25-F61BF80179EFQ34794030-CC31E890-D5DC-40F6-A4EF-DEBED32060A3Q34995420-FDE2B52E-E935-4679-8915-88D12AC6AD8DQ35800000-6ED2A761-8C29-4B36-87A3-0A0208CB5EF5Q35833536-7AA5C168-381A-4797-9C5F-03C68EB1380DQ35882729-B65A660D-9EB8-4C68-9927-3E0806545558Q36251998-FA81D671-0A06-450C-AA87-C108594FA0BFQ36639242-CE16CC41-5E63-4F22-87BB-90222A8AA6D3Q36925612-1499F90C-10B3-429C-943E-98B57D7472DCQ37000488-626A4E42-6F6B-4EB3-B198-3F560EB63DC7Q37055497-D216D06A-C908-4048-BD73-BFD841E09443Q37539279-DAB104CD-C299-4CAD-AD69-DA5E80ABB170Q38316783-4C90FD6C-EB15-4C53-BD74-349A86817D78Q38592451-FE1CC3B7-2995-4512-968E-E6E0CB68D95EQ38872085-F78B7250-1955-4D4F-9520-85B5465E6997Q38883083-58895F90-BD7C-437A-95CA-8F123E2DC558Q38950095-640D6862-3F1A-4628-9640-77DAB6019F86Q38983187-38C00B26-190D-4656-853C-5CF1710CA44AQ39118898-415C466F-8268-4ED5-BCCF-4B6CD8825222Q39270980-7212816D-6C7F-4459-BC6A-CD127E937C6DQ39313571-719289D3-30CA-4B0C-A9DC-B72DECC44C3DQ40825269-3D1A929B-5444-4725-9A32-39786B0EEF08Q41151197-BF48A19C-AFD7-4A07-B551-EC48AC8CF4CFQ41575678-A9DE8C2B-0974-4CA2-992D-2DA29DA40842Q41623603-84D82870-5623-40DE-8A9E-60612B7FE7ACQ41830631-E181C91F-EC9F-4DE2-A87F-663867A58ED5Q42353908-F1942C05-E64C-4594-B35A-08262D476BB4Q46152975-2A135045-43C3-43C8-BBB9-04C6217E1D9EQ46311193-F5F13D16-7F96-46A6-A97F-3D8CF3F7F1EAQ46671150-BDF1D327-2C62-496A-B518-D8C536EFCC00Q47251029-91D7C607-3686-4883-8F10-6223FAFCCE85Q47592140-5F078663-AD41-4661-984E-DFAF7758D5EDQ47689697-EF826A2D-426D-49E8-8C61-E9E920D50284Q50525085-11821477-4583-43BB-9CD3-9833F9C75C61Q55315355-AE569918-2E7C-4453-888B-D0F4A49FEBF1Q55353865-76D90460-4645-42EF-8D03-2F10C3E73114
P2860
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@ast
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@en
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@nl
type
label
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@ast
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@en
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@nl
prefLabel
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@ast
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@en
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@nl
P2093
P2860
P3181
P1433
P1476
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice
@en
P2093
David Theo Winkler
Florence Clavaguera
Graham Fraser
Karin Breu
Markus Tolnay
Michael Sinnreich
Michel Goedert
Perrine Castets
Sefika Ozcelik
Véronique Schaeffer
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0062459
P407
P577
2013-01-01T00:00:00Z